EPAS1 and cancer: These results are relevant in view of the recent development and clinical validation of HIF‐2α inhibitors targeting clear cell renal cell carcinomas (Cho et al, 2016), and thus warrant further studies on the applicability of combinatorial LDM + paralog‐specific HIFα antagonists in hypoxic and/or HIFα overexpressing cancers.